Holmium Iodide Hydrates: Synthesis and Properties

Heterogeneous equilibria in the Ho2O3-HI-H2O and HoI3-HI-H2O ternary aqueous systems at 25°C are studied by the isothermal method. The crystallization fields are established, and the compounds HoI3 · 9H2O and Ho2I(OH)5 · 2H2O are isolated. The compounds are characterized by chemical, crystal-optical, and thermogravimetric analyses and X-ray diffraction. As is shown by thermal analysis in air, stable intermediate phases of compositions HoOI · 3Ho2O3 and HoOI · Ho2O3 exist in the region from 370 to 600°C

Holmium Iodide Hydrates: Synthesis and Properties

Heterogeneous equilibria in the Ho2O3-HI-H2O and HoI3-HI-H2O ternary aqueous systems at 25°C are studied by the isothermal method. The crystallization fields are established, and the compounds HoI3 · 9H2O and Ho2I(OH)5 · 2H2O are isolated. The compounds are characterized by chemical, crystal-optical, and thermogravimetric analyses and X-ray diffraction. As is shown by thermal analysis in air, stable intermediate phases of compositions HoOI · 3Ho2O3 and HoOI · Ho2O3 exist in the region from 370 to 600°C

Peculiarities of electromagnetic waves absorption in polymer magnetic nanocomposites (La,Sr)MnO₃

The results of research of the nonresonant and magnetic resonance absorption of electromagnetic waves in polymer magnetic nanocomposites (La₀.₇Sr₀.₃Mn₀.₃) in 10-40 GHz and 60-78 GHz frequency bands are presented. The absorption magnitude up to -7.5 dB at 32-35 GHz has been detected for the composite with 60 % filling and a layer thickness of 0.53 mm. The analysis of results obtained proves a high level homogeneity of magnetic nanoparticles distribution in the polymer matrix. The most probable reasons of unusually large value of the spectroscopic splitting factor, obtained by Electron Spin Resonance technique, are under discussion. The results of design of the technology and the manufacturing technique of ferromagnetic composites together with epoxy-polysiloxane polymer matrix are presented

Иммуногенные и протективые свойства кандидатной пептидной вакцины против SARS-CoV-2

Background. In 2020, the pandemic caused by novel coronavirus infection has become one of the most critical global health challenges during the past century. The lack of a vaccine, as the most effective way to control the novel infection, has prompted the development of a large number of preventive products by the scientific community. We have developed a candidate vaccine (EpiVacCorona) against novel coronavirus infection caused by SARS-CoV-2 that is based on chemically synthesized peptides conjugated to a carrier protein and adsorbed on aluminum hydroxide and studied the specific activity of the developed vaccine. Aims study of the immunogenicity and protectivity of the peptide candidate vaccine EpiVacCorona. Methods. The work was performed using standard molecular biological, virological and histological methods. Results. It was demonstrated that EpiVacCorona, when administered twice, spaced 14 days apart, to hamsters, ferrets, and non-human primates (african green monkeys, rhesus macaques) at a dose of 260 g, which is equal to one inoculation dose for humans, induces virus-specific antibodies in 100% of the animals. Experiments in hamsters showed this vaccine to be associated with the dose-dependent immunogenicity. The vaccine was shown to accelerate the elimination of the virus from the upper respiratory tract in ferrets and prevent the development of pneumonia in hamsters and non-human primates following a respiratory challenge with novel coronavirus. Conclusions. The results of a preclinical specific activity study indicate that the use of EpiVacCorona has the potential for human vaccination.Обоснование. В 2020 г. пандемия, вызванная новой коронавирусной инфекцией, стала одним из самых серьезных испытаний для глобального здравоохранения за последнее столетие. Отсутствие вакцины как наиболее действенного способа борьбы против новой инфекции обусловило разработку научным сообществом большого количества профилактических препаратов. Нами была разработана кандидатная вакцина (ЭпиВакКорона) против новой коронавирусной инфекции SARS-CoV-2 на основе химически синтезированных пептидов, конъюгированных на белок-носитель и адсорбированных на гидроксид алюминия, и изучена ее специфическая активность. Цель исследования изучение иммуногенных и протективных свойств кандидатной пептидной вакцины ЭпиВакКорона. Методы. Работа была выполнена при помощи стандартных молекулярно-биологических, вирусологических и гистологических методов. Результаты. Показано, что ЭпиВакКорона при двукратном введении с интервалом в 14 дней хомякам, хорькам и низшим приматам (африканским зеленым мартышкам, макакам-резусам) в дозе 260 мкг, равной одной прививочной дозе для человека, вызывает индукцию вирусспецифических антител у 100% животных. В опытах на хомяках показано, что вакцинный препарат обладает дозозависимой иммуногенностью, вакцина индуцирует ускорение элиминации вируса из верхних дыхательных путей у хорьков и предотвращает развитие пневмонии у хомяков и низших приматов после респираторного заражения новым коронавирусом. Заключение. Результаты доклинического исследования специфической активности свидетельствуют о перспективности использования ЭпиВакКорона для вакцинации людей